Pluripotent stem cell (PSC) culture at commercial scale requires a shift from the current manual processing methods and costly materials to deliver affordable differentiated cell products in a repeatable and robust manner. The development of automated processing and analytical platforms for manufacturing allogeneic cell therapies derived from pluripotent stem cells is one of the aims of the Industrialisation group of the Cell and Gene Therapy Catapult (CGTC). This is centred around developing starting materials compliant with industry-standards, scalable 2D and 3D expansion systems as well as flexible downstream processing solutions. Here, we describe the current progress of CGTC’s Cell Plasticity platform programme with respect to developing automated processes for controlled expansion of pluripotent stem cells in 2D and 3D systems and strategies for culture intensification and integrated downstream processing solutions.
Cell Signaling / Transduction
Research And Development
Manufacturer & Biotech/pharma12%
Medical Device Company6%